Khurshed Bozorov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Khurshed Bozorov has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Haji Akber Aisa
Chinese Academy of Sciences
20 shared publications Li Fei Nie
Key Laboratory of Plant Resources and Chemistry in Arid Regions, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Ürümqi, People’s Republic of China
8 shared publicationsJiangyu Zhao
State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization and the Key Laboratory of Plant Resources in Arid Regions, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, 40-1 South Beijing Rd, Urumqi 830011, China; University of Chinese Academy of Sciences, Yuquan Rd 19 A, Beijing 100049, China
7 shared publications- Jiangyu Zhao
State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, South Beijing Rd 40-1, Urumqi 830011, China
7 shared publications - Zhishen Ge
Xi’an Jiaotong University
7 shared publications - Guozheng Huang
School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma’anshan, People’s Republic of China
6 shared publications
Latest Publications
- 12 November 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
A Biomimetic Cell Membrane-Coated Nanoreactor Reshapes ROS Homeostasis and Activates STING Pathway for Synergistic Chemodynamic–Immunotherapy
The combination of chemodynamic therapy (CDT) and immunotherapy offers a promising therapeutic paradigm for advanced cancer treatment, yet its translation is largely hindered by inadequate intratumoral reactive oxygen species (ROS) production and the lack of a robust link between ROS-induced cytotoxicity and durable immune activation. To address these challenges, we herein engineer a multifunctional biomimetic nanoplatform (ZMGM) by encapsulating Mn2+ and glucose oxidase (GOX) within zeolitic imidazolate framework-8 (ZIF-8), followed by surface functionalization with 4T1 breast cancer cell membranes. This design integrates three synergistic functions: (1) GOX depletes glucose and generates hydrogen peroxide (H2O2) within the acidic tumor microenvironment; (2) the produced H2O2 fuels the Mn2+-mediated Fenton-like reaction to amplify ROS production; and (3) Mn2+ simultaneously serves as a potent stimulator of interferon genes (STING) agonist, triggering type-I interferon responses and promoting dendritic cell maturation. Meanwhile, the homologous cancer cell membrane coating endows ZMGM with specific tumor homing and enhanced tumor localization. Both in vitro and in vivo findings demonstrate that ZMGM not only efficiently eradicates primary tumors but also induces a systemic antitumor immune response, characterized by increased CD8+ T cell infiltration, that effectively suppresses distant metastatic lesions. Notably, the synergistic CDT–STING immunotherapy achieves a primary tumor inhibition rate of 84.22% without obvious systemic toxicity. This work provides a paradigm for rationally designing a single nanoplatform that bridges ROS-mediated cell killing and innate immune activation, offering a promising avenue for combating metastatic triple-negative breast cancer.
- 12 November 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
A Biomimetic Cell Membrane-Coated Nanoreactor Reshapes ROS Homeostasis and Activates STING Pathway for Synergistic Chemodynamic–Immunotherapy
The combination of chemodynamic therapy (CDT) and immunotherapy offers a promising therapeutic paradigm for advanced cancer treatment, yet its translation is largely hindered by inadequate intratumoral reactive oxygen species (ROS) production and the lack of a robust link between ROS-induced cytotoxicity and durable immune activation. To address these challenges, we herein engineer a multifunctional biomimetic nanoplatform (ZMGM) by encapsulating Mn2+ and glucose oxidase (GOX) within zeolitic imidazolate framework-8 (ZIF-8), followed by surface functionalization with 4T1 breast cancer cell membranes. This design integrates three synergistic functions: (1) GOX depletes glucose and generates hydrogen peroxide (H2O2) within the acidic tumor microenvironment; (2) the produced H2O2 fuels the Mn2+-mediated Fenton-like reaction to amplify ROS production; and (3) Mn2+ simultaneously serves as a potent stimulator of interferon genes (STING) agonist, triggering type-I interferon responses and promoting dendritic cell maturation. Meanwhile, the homologous cancer cell membrane coating endows ZMGM with specific tumor homing and enhanced tumor localization. Both in vitro and in vivo findings demonstrate that ZMGM not only efficiently eradicates primary tumors but also induces a systemic antitumor immune response, characterized by increased CD8+ T cell infiltration, that effectively suppresses distant metastatic lesions. Notably, the synergistic CDT–STING immunotherapy achieves a primary tumor inhibition rate of 84.22% without obvious systemic toxicity. This work provides a paradigm for rationally designing a single nanoplatform that bridges ROS-mediated cell killing and innate immune activation, offering a promising avenue for combating metastatic triple-negative breast cancer.
- Open Access
- 10 October 2026
- Published by Kokand State Pedagogical Institute in Qo‘qon DPI. Ilmiy xabarlar jurnali
- Vol. 8 (9) , 826-834
DESIGN OF NOVEL TRICYCLIC ARYLIDENE THIENO[3,2- d]PYRIMIDINONES
A novel polycyclic arylidene thieno[3,2-d]pyrimidinone, (E)-5-(2,4- dimethoxybenzylidene)-3-methyl-6,7-dihydropyrrolo[1,2-a]thieno[3,2-d]pyrimidin-9(5H)- one (6a-b), was synthesized from ethyl 3-amino-4-methylthiophene-2-carboxylate (3) through a two-step cyclization sequence followed by condensation of the α-methylene moiety with an aromatic aldehyde. The synthetic strategy enabled sequential construction of the fused heterocyclic framework and subsequent introduction of an arylidene fragment at the reactive α-methylene position. The structures of the synthesized intermediates and target compound were characterized by 1H and 13C NMR spectroscopy and high-resolution mass spectrometry (HRMS). The obtained results demonstrate the applicability of this synthetic approach to the preparation of structurally differentiated polycyclic thieno[3,2- d]pyrimidinone derivatives.
- 10 October 2026
- Published by Kokand State Pedagogical Institute in Qo‘qon DPI. Ilmiy xabarlar jurnali
- Vol. 8 (9) , 826-834
Open AccessDESIGN OF NOVEL TRICYCLIC ARYLIDENE THIENO[3,2- d]PYRIMIDINONES
A novel polycyclic arylidene thieno[3,2-d]pyrimidinone, (E)-5-(2,4- dimethoxybenzylidene)-3-methyl-6,7-dihydropyrrolo[1,2-a]thieno[3,2-d]pyrimidin-9(5H)- one (6a-b), was synthesized from ethyl 3-amino-4-methylthiophene-2-carboxylate (3) through a two-step cyclization sequence followed by condensation of the α-methylene moiety with an aromatic aldehyde. The synthetic strategy enabled sequential construction of the fused heterocyclic framework and subsequent introduction of an arylidene fragment at the reactive α-methylene position. The structures of the synthesized intermediates and target compound were characterized by 1H and 13C NMR spectroscopy and high-resolution mass spectrometry (HRMS). The obtained results demonstrate the applicability of this synthetic approach to the preparation of structurally differentiated polycyclic thieno[3,2- d]pyrimidinone derivatives.
- Open Access
- 10 October 2026
- Published by Kokand State Pedagogical Institute in Qo‘qon DPI. Ilmiy xabarlar jurnali
- Vol. 8 (9) , 835-843
SYNTHESIS OF NOVEL POLYCYCLIC ARYLIDENE THIENO[3,2- d]PYRIMIDINONES
A concise synthetic route was developed for brominated polycyclic thieno[3,2-d]pyrimidinones through sequential cyclocondensation and α-methylene condensation. Ethyl 3-amino-5-bromobenzo[b]thiophene-2-carboxylate was prepared from 5- bromo-2-chlorobenzonitrile and ethyl 2-mercaptoacetate under basic conditions. Subsequent reactions with cyclic lactams afforded fused derivatives with different ring sizes. Condensation with aromatic aldehydes provided arylidene products. Structural characterization by 1H/13C NMR spectroscopy and HRMS confirmed the proposed molecular frameworks, establishing a practical platform for further functionalization.
- 10 October 2026
- Published by Kokand State Pedagogical Institute in Qo‘qon DPI. Ilmiy xabarlar jurnali
- Vol. 8 (9) , 835-843
Open AccessSYNTHESIS OF NOVEL POLYCYCLIC ARYLIDENE THIENO[3,2- d]PYRIMIDINONES
A concise synthetic route was developed for brominated polycyclic thieno[3,2-d]pyrimidinones through sequential cyclocondensation and α-methylene condensation. Ethyl 3-amino-5-bromobenzo[b]thiophene-2-carboxylate was prepared from 5- bromo-2-chlorobenzonitrile and ethyl 2-mercaptoacetate under basic conditions. Subsequent reactions with cyclic lactams afforded fused derivatives with different ring sizes. Condensation with aromatic aldehydes provided arylidene products. Structural characterization by 1H/13C NMR spectroscopy and HRMS confirmed the proposed molecular frameworks, establishing a practical platform for further functionalization.
- 9 October 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (41) , 45216-45234
X-ray-Triggered Self-Sustaining Afterglow Scaffolds with Persistent Type-I/II ROS Generation for Imaging-Guided Hypoxic Tumor Therapy
Afterglow imaging-guided photodynamic therapy (PDT) eliminates tissue autofluorescence and enables real-time therapeutic monitoring, yet its efficacy is constrained by shallow light penetration and tumor hypoxia. X-ray activation overcomes the depth barrier, but an integrated platform that simultaneously addresses hypoxia and provides persistent afterglow feedback remains lacking. Herein, we report a self-sustaining afterglow scaffold (TBR) constructed from a triphenylamine-derived sulfur-containing heterocycle bearing a p-dimethylaminophenylvinyl terminal group, featuring a donor−π–donor−π–acceptor (D−π–D−π–A) architecture around an aggregation-induced emission core. After nanoprecipitation with Pluronic F127, TBR nanoparticles (TBR-NPs) adopt a fluorescence-quenched state enabled by an ultrasmall singlet–triplet energy gap, thereby maximizing X-ray energy conversion to generate both oxygen-independent type-I (•OH, O2•–) and type-II (1O2) reactive oxygen species (ROS). Critically, the initially generated ROS undergo cycloaddition with TBR to form a cyclic peroxide intermediate; spontaneous dark decomposition releases stored chemical energy, re-exciting adjacent TBR molecules to sustain ROS production and generate near-infrared afterglow via a chemically initiated electron exchange luminescence (CIEEL) mechanism. This self-sustaining loop enables fractionated X-ray regimens that yield higher cumulative ROS than continuous exposure, while the type-I pathway ensures efficacy under hypoxia. A tumor-activatable derivative (BTBR) with H2O2-responsive boronate caging achieves high-contrast, tumor-specific afterglow imaging (signal-to-background ratio > 120) and enables hypoxic tumor ablation (95.8% inhibition) with real-time afterglow monitoring. By establishing a unified molecular platform that overcomes the dual barriers of penetration depth and hypoxia, this work provides a robust and generalizable strategy for advancing X-ray-triggered afterglow imaging-guided cancer therapy.
- 9 October 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (41) , 45216-45234
X-ray-Triggered Self-Sustaining Afterglow Scaffolds with Persistent Type-I/II ROS Generation for Imaging-Guided Hypoxic Tumor Therapy
Afterglow imaging-guided photodynamic therapy (PDT) eliminates tissue autofluorescence and enables real-time therapeutic monitoring, yet its efficacy is constrained by shallow light penetration and tumor hypoxia. X-ray activation overcomes the depth barrier, but an integrated platform that simultaneously addresses hypoxia and provides persistent afterglow feedback remains lacking. Herein, we report a self-sustaining afterglow scaffold (TBR) constructed from a triphenylamine-derived sulfur-containing heterocycle bearing a p-dimethylaminophenylvinyl terminal group, featuring a donor−π–donor−π–acceptor (D−π–D−π–A) architecture around an aggregation-induced emission core. After nanoprecipitation with Pluronic F127, TBR nanoparticles (TBR-NPs) adopt a fluorescence-quenched state enabled by an ultrasmall singlet–triplet energy gap, thereby maximizing X-ray energy conversion to generate both oxygen-independent type-I (•OH, O2•–) and type-II (1O2) reactive oxygen species (ROS). Critically, the initially generated ROS undergo cycloaddition with TBR to form a cyclic peroxide intermediate; spontaneous dark decomposition releases stored chemical energy, re-exciting adjacent TBR molecules to sustain ROS production and generate near-infrared afterglow via a chemically initiated electron exchange luminescence (CIEEL) mechanism. This self-sustaining loop enables fractionated X-ray regimens that yield higher cumulative ROS than continuous exposure, while the type-I pathway ensures efficacy under hypoxia. A tumor-activatable derivative (BTBR) with H2O2-responsive boronate caging achieves high-contrast, tumor-specific afterglow imaging (signal-to-background ratio > 120) and enables hypoxic tumor ablation (95.8% inhibition) with real-time afterglow monitoring. By establishing a unified molecular platform that overcomes the dual barriers of penetration depth and hypoxia, this work provides a robust and generalizable strategy for advancing X-ray-triggered afterglow imaging-guided cancer therapy.
- 21 September 2026
- Published by Elsevier in Phytochemistry
- Vol. 253
Menthane-type monoterpenes from Achillea biebersteinii Afan.: Stereochemical elucidation and anti-inflammatory activity
- 21 September 2026
- Published by Elsevier in Phytochemistry
- Vol. 253
Menthane-type monoterpenes from Achillea biebersteinii Afan.: Stereochemical elucidation and anti-inflammatory activity
- 16 September 2026
- Published by Elsevier in Phytochemistry
- Vol. 253
Coumarin derivatives from Ferula kuhistanica and their biological activities
- 16 September 2026
- Published by Elsevier in Phytochemistry
- Vol. 253
Coumarin derivatives from Ferula kuhistanica and their biological activities
- Open Access
- 20 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7457
Thieno[3,2-d]pyrimidines in Anticancer Drug Discovery: Recent Advances in Drug Design and Molecular Targets
The thieno[3,2-d]pyrimidine scaffolds have emerged as an important class of heterocycles in anticancer drug discovery, with clinically advanced drugs olmutinib and pictilisib highlighting their therapeutic potential. This review presents thieno[3,2-d]pyrimidine-containing anticancer agents reported between January 2008 and August 2025, focusing on synthetic methodologies, anticancer-related biological activities, and structure–activity relationships. Thieno[3,2-d]pyrimidine derivatives have been investigated as inhibitors of numerous cancer-related targets, including EGFR, PI3K/mTOR, CDKs, JAK, VEGFR, HDAC, ATR, and other oncogenic proteins. This review also summarizes thieno[3,2-d]pyrimidine scaffolds with anticancer activity, with particular emphasis on the design and synthesis of lead compounds, molecular hybridization strategies, and recent advances in this area. Synthetic pathways for lead compounds are systematically presented and discussed, along with pharmacophoric features. In addition, detailed structure–activity relationship analyses are provided to highlight the influence of heterocyclic fusion, linker optimization, hydrogen-bonding motifs, electronic effects, hydrophobic fragments, and the introduction of hybrid scaffolds on antiproliferative potency, kinase inhibition, selectivity, and multitarget activity. In addition, this review demonstrates the significant potential of thieno[3,2-d]pyrimidine-based scaffolds as a privileged platform for the development of next-generation targeted anticancer agents and offers valuable guidance for future medicinal chemistry research.
- 20 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7457
Open AccessThieno[3,2-d]pyrimidines in Anticancer Drug Discovery: Recent Advances in Drug Design and Molecular Targets
The thieno[3,2-d]pyrimidine scaffolds have emerged as an important class of heterocycles in anticancer drug discovery, with clinically advanced drugs olmutinib and pictilisib highlighting their therapeutic potential. This review presents thieno[3,2-d]pyrimidine-containing anticancer agents reported between January 2008 and August 2025, focusing on synthetic methodologies, anticancer-related biological activities, and structure–activity relationships. Thieno[3,2-d]pyrimidine derivatives have been investigated as inhibitors of numerous cancer-related targets, including EGFR, PI3K/mTOR, CDKs, JAK, VEGFR, HDAC, ATR, and other oncogenic proteins. This review also summarizes thieno[3,2-d]pyrimidine scaffolds with anticancer activity, with particular emphasis on the design and synthesis of lead compounds, molecular hybridization strategies, and recent advances in this area. Synthetic pathways for lead compounds are systematically presented and discussed, along with pharmacophoric features. In addition, detailed structure–activity relationship analyses are provided to highlight the influence of heterocyclic fusion, linker optimization, hydrogen-bonding motifs, electronic effects, hydrophobic fragments, and the introduction of hybrid scaffolds on antiproliferative potency, kinase inhibition, selectivity, and multitarget activity. In addition, this review demonstrates the significant potential of thieno[3,2-d]pyrimidine-based scaffolds as a privileged platform for the development of next-generation targeted anticancer agents and offers valuable guidance for future medicinal chemistry research.
- 28 July 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (7) , e71537
Chiral Coumarin Enantiomers From Prangos pabularia Roots: Absolute Configuration, Tyrosinase Activation, and Anti‐Vitiligo Potential in B16F10 Cells
In order to isolate and characterize enantiomeric compounds from the roots of Prangos pabularia the dichloromethane extract was extensively fractionated by column chromatography, flash, semi‐preparative high performance liquid chromatography (HPLC), and chiral HPLC. Six pairs of enantiomers were isolated from dichloromethane extracts using preparative chiral HPLC. The absolute configurations of the isolated isomers were identified using circular dichroism (CD). The anti‐vitiligo activities of the corresponding (S)‐ and (R) ‐enantiomers were assessed by determining their tyrosinase activation rates. ( S )‐Pangelin 9 (PPE19‐1) showed higher activity with 125.42% than ( R )‐pangelin 10 (PPE19‐2) with 120.6%, while the positive control (8‐methoxypsoralen) resulted in 122.3%. The percentage of activation rate of ( S )‐oxypeucidanin hydrate 1 (PPE4‐1) was 119.74%, while it was 110.01% for ( R ) oxypeucidanin hydrate 2 (PPE4‐2). We conclude that the ( S, R ) enantiomers of pangelin and oxypeucidanin hydrate ( S, R ) may be useful as pigmentation‐promoting agents for the treatment of vitiligo.
- 28 July 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (7) , e71537
Chiral Coumarin Enantiomers From Prangos pabularia Roots: Absolute Configuration, Tyrosinase Activation, and Anti‐Vitiligo Potential in B16F10 Cells
In order to isolate and characterize enantiomeric compounds from the roots of Prangos pabularia the dichloromethane extract was extensively fractionated by column chromatography, flash, semi‐preparative high performance liquid chromatography (HPLC), and chiral HPLC. Six pairs of enantiomers were isolated from dichloromethane extracts using preparative chiral HPLC. The absolute configurations of the isolated isomers were identified using circular dichroism (CD). The anti‐vitiligo activities of the corresponding (S)‐ and (R) ‐enantiomers were assessed by determining their tyrosinase activation rates. ( S )‐Pangelin 9 (PPE19‐1) showed higher activity with 125.42% than ( R )‐pangelin 10 (PPE19‐2) with 120.6%, while the positive control (8‐methoxypsoralen) resulted in 122.3%. The percentage of activation rate of ( S )‐oxypeucidanin hydrate 1 (PPE4‐1) was 119.74%, while it was 110.01% for ( R ) oxypeucidanin hydrate 2 (PPE4‐2). We conclude that the ( S, R ) enantiomers of pangelin and oxypeucidanin hydrate ( S, R ) may be useful as pigmentation‐promoting agents for the treatment of vitiligo.
- Open Access
- 17 July 2026
- Published by Elsevier in Asian Journal of Pharmaceutical Sciences
- Vol. 21 (4)
Engineered GLUT1-targeted STING polyproagonists: Redox-triggered activation and enhanced endosomal escape for cancer immunotherapy
- 17 July 2026
- Published by Elsevier in Asian Journal of Pharmaceutical Sciences
- Vol. 21 (4)
Open AccessEngineered GLUT1-targeted STING polyproagonists: Redox-triggered activation and enhanced endosomal escape for cancer immunotherapy
- Open Access
- 13 July 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
Spatiotemporal “cut-and-repair” cascade: A cross-omics driven nanoemulsion breaks the gut–brain vicious cycle in Alzheimer's disease
- 13 July 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
Open AccessSpatiotemporal “cut-and-repair” cascade: A cross-omics driven nanoemulsion breaks the gut–brain vicious cycle in Alzheimer's disease